Last updated: 2026-09-05 00:59:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Biohaven Ltd. (BHVN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $15,68, with a market capitalization of $2,37B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $7,48 to $18,57. This page covers its latest market performance, valuation, price trends and company information.
$2,37B | |
$15,52 | |
$152,56 | |
$7,10 | |
$15,86 | |
1,60M | |
-- | |
-- | |
$18,57 | |
$7,48 | |
-- | |
-- |
Biohaven Ltd. (BHVN) last closed at $15,86 as of 2026-09-04 23:23:40, unchanged from the previous close of $15,86.
During the latest regular trading session, BHVN traded between $7,10 and $152,56, with a volume of 1,60M shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Biohaven Ltd. (BHVN) moved from $15,46 to $15,68, representing a gain of 1,44% ($0,22).
The stock traded between $15,27 and $15,79 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 2,94 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 74,0%
BHVN is currently trading at $15,68, placing it 74,0% of the way from its 52-week low of $7,48 to its 52-week high of $18,57. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 274 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Biohaven Ltd. (BHVN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.